Regence

Medicare Advantage Policy Manual

Investigational (Experimental) Services and New and Emerging Medical Technologies and Procedures

Published: 10/01/2018

Next Review: 12/2018

Last Review: 09/2018

Medicare Link(s) Revised: 10/01/2018

IMPORTANT REMINDER

The Medicare Advantage Medical Policy manual is not intended to override the member Evidence of Coverage (EOC), which defines the insured’s benefits, nor is it intended to dictate how providers are to practice medicine. Physicians and other health care providers are expected to exercise their medical judgment in providing the most appropriate care for the individual member.

The Medicare Advantage Medical Policies are designed to provide guidance regarding the decision-making process for the coverage or non-coverage of services or procedures in accordance with the member EOC and the Centers of Medicare and Medicaid Services (CMS) policies, when available. In the event of a conflict, applicable CMS policy or EOC language will take precedence over the Medicare Advantage Medical Policy. In the absence of CMS guidance for a requested service or procedure, the health plan may apply their Medical Policy Manual or MCG™ criteria, both of which are developed with an objective, evidence-based process using scientific evidence, current generally accepted standards of medical practice, and authoritative clinical practice guidelines.

Medicare and EOCs exclude from coverage, among other things, services or procedures considered to be investigational, cosmetic, or not medically necessary, and in some cases, providers may bill members for these non-covered services or procedures. Providers are encouraged to inform members in advance when they may be financially responsible for the cost of non-covered or excluded services.

DESCRIPTION

INVESTIGATIONAL (EXPERIMENTAL) SERVICES

Title XVIII of the Social Security Act, Section 1862(a)(1)(A) prohibits Medicare coverage for items and services which are not “reasonable and necessary” for the diagnosis and treatment of an injury or illness or to improve the functioning of a malformed body member. According to the Medicare Claims Processing Manual, Chapter 23, §30.A, if a procedure or device lacks scientific evidence regarding safety and efficacy because it is investigational or experimental, the service is noncovered because it is not reasonable and necessary to treat illness or injury.[2]
In the absence of a national coverage determination (NCD), local coverage determination (LCD), or other Medicare coverage guidance, Medicare regulations allow a Medicare Advantage Organization (MAO) to make its own coverage determination, applying an objective, evidence-based process, based on authoritative evidence.[3]

The Noridian LCD for Non-Covered Services (L35008) states, “It is important to note that the fact that a new service or procedure has been issued a CPT code or is FDA approved for a specific indication does not, in itself, make the procedure medically reasonable and necessary.” In addition, the presence of a payment amount in the Medicare Physicians’ Fee Schedule (MPFS) does not imply that Medicare has determined the service to be a “reasonable and necessary” covered service.[2]

Requests for health care services, treatments, procedures, or devices that are not addressed in an NCD, LCD, or other Medicare reference, or not specified as “covered” in Medicare benefit manuals or other transmittals may be reviewed to ensure sufficient evidence regarding safety and efficacy is available, ensuring the services are medically reasonable and necessary for members. (See the “Policy Guidelines” below for important notes regarding Medicare and investigational services.)

**MEDICARE ADVANTAGE POLICY CRITERIA**

**Note:** This Medicare Advantage medical policy does not address services provided in the context of a clinical trial, or medical devices related to Category A or B Investigational Device Exemption (IDE) studies. For Clinical Trial and IDE study claim assistance, see the Centers for Medicare and Medicaid Services (CMS) website. (See Cross References)

Procedures and items that are subject to Coverage with Evidence Development (CED) criteria may be addressed in separate Medicare Advantage medical policies when those services are reviewed by the health plan.[1] National coverage determinations (NCDs) that require CED can be found on the CMS web page for Coverage with Evidence Development. (See Cross References)

The following are new and emerging medical technologies reported with Category III CPT Codes. According to the Noridian Local Coverage Determination (LCD) for Non-Covered Services (L35008), all new Category III Codes are considered non-covered unless specifically approved for payment by CMS or the Noridian Healthcare Solutions (Noridian) medical directors and documented as approved in a published LCD or article (LCA). In most cases, these codes have been created to track new, unproven therapies and tests.

**IMPORTANT NOTE:** This list is updated routinely to supply the most recent Category III codes, as they are released. It is not intended to be an all-inclusive list. The absence or removal of a Category III code from this medical policy does not imply coverage. Some procedures may be addressed in other Medicare Advantage medical policies, while others may be non-covered, even when not found in any medical policy. Please see
available Medicare Advantage medical policies for specific procedures, as well as the Noridian LCD for Non-Covered Services (L35008) and the LCA for Additional Information Required for Coverage and Pricing for Category III CPT® Codes (A55681), for additional Category III codes.

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
<th>Test Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>0346T</td>
<td>Ultrasound, elastography (List separately in addition to code for primary procedure)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0505T</td>
<td>Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0506T</td>
<td>Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0507T</td>
<td>Near-infrared dual imaging (ie, simultaneous reflective and transilluminated light) of meibomian glands, unilateral or bilateral, with interpretation and report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0508T</td>
<td>Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Proprietary Laboratory Analyses (PLA) Codes

The following laboratory tests are considered “not medically reasonable or necessary” under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). Jurisdiction of claims for laboratory services furnished by an independent laboratory normally lies with the carrier serving the area in which the laboratory test is performed. Specific Medicare guidance for each test is noted below:

IMPORTANT NOTE: This list is updated routinely with PLA codes as they are released. It is not intended to be an all-inclusive list. The absence of a PLA test code from this medical policy does not imply coverage, as some PLA tests may be addressed in other Medicare Advantage medical policies.

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
<th>Test Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>0052U</td>
<td>Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation</td>
<td>VAP Cholesterol Test</td>
<td>VAP Diagnostics Laboratory, Inc. (Birmingham, AL)</td>
</tr>
</tbody>
</table>

✓ MoIDX: Biomarkers in Cardiovascular Risk Assessment ([L36129](https://www.medicare.gov/coverage) (Medicare has coverage for defined cholesterol tests. Non-
Medicine

0058U Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative

- The MolDX Program requires labs to submit a technology assessment (TA) to provide evidence of analytical and clinical validity (AV/CV), and clinical utility (CU). *(Noridian LCA A54554)*

- The Noridian LCD L36256 states reimbursement is only allowed for “approved tests… for dates of service consistent with the effective date of the coverage determination” after MolDX review.

- If a test does not have a coverage determination, then coverage is not allowed because evidence of clinical validity or utility has not been established via the TA review process.

- This test is not considered medically reasonable and necessary under SSA §1862(a)(1)(A) until a MolDX review is complete and coverage is indicated by MolDX or Noridian.

Merkel SmT Oncoprotein Antibody Titer test

University of Washington, Department of Laboratory Medicine (Seattle, WA)

0059U Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative

- The MolDX Program requires labs to submit a technology assessment (TA) to provide evidence of analytical and clinical validity (AV/CV), and clinical utility (CU). *(Noridian LCA A54554)*

- The Noridian LCD L36256 states reimbursement is only allowed for “approved tests… for dates of service consistent with the effective date of the coverage determination” after MolDX review.

- If a test does not have a coverage determination, then coverage is not allowed because evidence of clinical validity or utility has not been established via the TA review process.

- This test is not considered medically reasonable and necessary under SSA §1862(a)(1)(A) until a MolDX review is complete and coverage is indicated by MolDX or Noridian.

Merkel Virus VP1 Capsid Antibody test

University of Washington, Department of Laboratory Medicine (Seattle, WA)

0061U Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1}

Transcutaneous multispectral measurement of tissue oxygenation
and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis

- The MolDX Program requires labs to submit a technology assessment (TA) to provide evidence of analytical and clinical validity (AV/CV), and clinical utility (CU). *(Noridian LCA A54552)*

- The Noridian **LCD L35160** states reimbursement is only allowed for “approved tests… for dates of service consistent with the effective date of the coverage determination” after MolDX review.

- If a test does not have a coverage determination, then coverage is not allowed because evidence of clinical validity or utility has not been established via the TA review process.

- This test is not considered medically reasonable and necessary under SSA §1862(a)(1)(A) until a MolDX review is complete and coverage is indicated by MolDX or Noridian.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Provider</th>
</tr>
</thead>
<tbody>
<tr>
<td>0062U</td>
<td>Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score</td>
<td><strong>SLE-key Rule Out</strong> Veracis (Virginia)</td>
</tr>
</tbody>
</table>

- With limited exceptions (such as single gene tests), the MolDX Program requires labs to submit a technology assessment (TA) to provide evidence of analytical and clinical validity (AV/CV), and clinical utility (CU). This is especially applicable to new tests (e.g., tests with multiple genes with or without algorithmic analysis with diagnostic and/or prognostic purposes that have not received FDA companion diagnostic status or been universally recognized by recognized authorities such as NCCN, ASCO or other professional societies). *(Noridian LCA L36807)*

- The Noridian LCD L35025 states reimbursement is only allowed for “approved tests… for dates of service consistent with the effective date of the coverage determination” after MolDX review.

- If a test does not have a coverage determination, then coverage is not allowed because evidence of clinical validity or utility has not been established via the TA review process.

- This test is not considered medically reasonable and necessary under SSA §1862(a)(1)(A) until a MolDX review is complete and coverage is indicated by MolDX or Noridian.
Finally, in order to be a Medicare-approved diagnostic test, the test must be ordered by a physician who is treating the beneficiary and the test results must be used in the management of a beneficiary’s specific medical problem. Although many molecular diagnostic tests may provide valid and useful information, they do not meet this definition. ([MolDX website](MolDX website))

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0063U</td>
<td>Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder</td>
</tr>
</tbody>
</table>

Molecular Pathology Procedures ([L35000](Molecular Pathology Procedures)) *(Specifically see the language in the LCD that reads, “Molecular pathology tests for diseases or conditions that manifest severe signs or symptoms in newborns and in early childhood or that result in early death… could be subject to automatic denials since these tests are not usually relevant to a Medicare beneficiary.”)*

To determine whether a medical technology is a proven, medically necessary service, device, or procedure, the MAO conducts literature searches and evaluates the published scientific evidence related to each technology. The published evidence is reviewed against five (5) technology assessment criteria. In order for a technology to be considered medically necessary, all five (5) criteria must be met. If any one or more of the following criteria are not met, then the technology is considered investigational:

1. The technology must have final approval from the appropriate government regulatory bodies (i.e., Food and Drug Administration [FDA]). An approval granted as an interim step (i.e., Treatment IND) in the governmental body’s regulatory process is not sufficient.
2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and consist of well-designed and well-conducted investigations published in peer-reviewed journals. The quality of the studies and the consistency of the results are considered when evaluating the evidence.
3. The technology must improve the net health outcome (the technology’s beneficial effects on health outcomes should outweigh any harmful effects on health outcomes).
4. The technology must be as beneficial as any established alternatives. This means the technology should improve the net health outcome as much as or more than established alternatives.
5. The improvement must be attainable outside the investigational settings. When used under the usual conditions of medical practice, the technology should be reasonably expected to satisfy technology evaluation criteria #3 and #4.

In addition to the above criteria, the following additional criteria apply to new diagnostic technologies (e.g., imaging studies, laboratory procedures, home monitoring devices):

1. Technical feasibility is demonstrated, including reproducibility and precision. For comparison among studies, a common standardized protocol for the new diagnostic technology is established.
2. For accurate interpretation of study results, sensitivities, specificities, and positive and negative predictive values compared to standards are established.
3. The clinical utility of a diagnostic technique, i.e., how the results of the study can be used to benefit patient management, is established. The clinical utility of both positive and negative tests must be established.

CROSS REFERENCES

Clinical Trials and Investigational Device Exemption (IDE) Studies, Medicine, Policy No. M-150
Coverage with Evidence Development (CED) Studies and Registries, Medicine, Policy No. M-156
Various Medicare Advantage medical policies for specific procedures, services, or devices

REFERENCES

1. Medicare Managed Care Manual, Chapter 4 - Benefits and Beneficiary Protections, §10.7.3 – Payment for Clinical Studies Approved Under Coverage with Evidence Development (CED)
2. Medicare Claims Processing Manual, Chapter 23 - Fee Schedule Administration and Coding Requirements, §30 - Services Paid Under the Medicare Physician’s Fee Schedule, A. Physician’s Services
3. Medicare Managed Care Manual, Chapter 4 - Benefits and Beneficiary Protections, §90.5 – Creating New Guidance
4. Noridian LCA for Additional Information Required for Coverage and Pricing for Category III CPT® Codes (A55681)
5. Medicare Claims Processing Manual, Chapter 1 - General Billing Requirements, §10.1.5.4 - Independent Laboratories

*IMPORTANT NOTE: Medicare Advantage medical policies use the most current Medicare references available at the time the policy was developed. Links to Medicare references will take viewers to external websites outside of the health plan’s web control as these sites are not maintained by the health plan.